Protease-Directed Drug Discovery

Gene Family Targeted Molecular Design

Volumn , Issue , 2008, Pages 159-197

  Sedrani, Richard ^a   Hommel, Ulrich ^a   Eder, Jörg ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aspartic proteases and catalytic mechanisms; Protease directed drug discovery; Serine proteases as drug targets

Indexed keywords

EID: 70450217959     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470423936.ch6     Document Type: Chapter

References (80)

1. Abbenante G, Fairlie DP, 2005. Protease inhibitors in the clinic. Med. Chem. 1(1):71-104.
2. Andreeva NS, Rumsh LD, 2001. Analysis of crystal structures of aspartic proteinases: on the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymes. Protein Sci. 10:2439-2450.
3. Ashworth DM, Atrash B, Baker GR, Baxter AJ, Jenkins PD, Jones DM, Szelke M, 1996a. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Biorg. Med. Chem. Lett. 6:1163-1166.
4. Ashworth DM, Atrash B, Baker GR, Baxter AJ, Jenkins PD, Jones DM, Szelke M, 1996b. 2-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Biorg. Med. Chem. Lett. 6:2475-2748.
5. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT, 2005. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 11:1805-1843.
6. Barrett AJ, Rawlings ND, Woessner JF, 1998. Handbook of Proteolytic Enzymes. Academic Press, San Diego.
7. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci J-E, Edris WA, Sutherlin DP, Green DR, Salvesen GS, 2003. A unified model for apical caspase activation. Mol. Cell 11(2):529-541.
8. Brandstetter H, Grams F, Glitz D, Lang A, Huber R, Bode W, Krell H-W, Engh RA, 2001. The 1.8-Å crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J. Biol. Chem. 276(20):17405-17412.
9. Brockunier L H J, Colwell Jr LF, Habulihaz B, He H, Leiting B, Lyons KA, Marsilio F, Patel R, Teffera Y, Wu JK, Thornberry NA, Weber AE, Parmee ER, 2004. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 14:4763-4766.
10. Brown FJ, Andisik DW, Bernstein PR, Bryant CB, Ceccarelli C, Damewood Jr JR, Edwards PD, Earley RA, Feeney S, Green RC, Gomes EP, Kosmider BJ, Krell RD, Shaw A, Steelman GB, Thomas RM, Vacek EP, Veale CA, Tithill PA, Warner P, Williams JC, Wolanin DJ, Woolson SA, 1994. Design of orally active, non-peptidic inhibitors of human leukocyte elastase. J. Med. Chem. 37(9):1259-1261.
11. Byers LD, Wolfenden R, 1972. A potent reversible inhibitor of carboxypeptidase A. J. Biol. Chem. 247(2):606-608.
12. Casimiro-Garcia A, Dudley DA, Heemstra RJ, Filipski KJ, Bigge CF, Edmunds JJ, 2006. Progress in the discovery of factor Xa inhibitors. Expert Opin. Ther. Patents 16:119-145.
13. Cody WL, Holsworth DD, Powell NA, Jalaie M, Zhang E, Wang W, Samas B, Bryant J, Ostroski R, Ryan MJ, Edmunds JJ, 2005. The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors. Bioorg. Med. Chem. 13:59-68.
14. Condon JS, Joseph-McCarthy D, Levin JI, Lombart H-G, Lovering FE, Sun L, Wang W, Xu W, Zhang Y, 2007. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg. Med. Chem. Lett. 17(1):34-39.
15. Cooper JB, 2002. Aspartic proteinases in disease: a structural perspective. Curr. Drug. Targets 3:155-173.
16. Dash C, Kulkarni A, Dunn B, Rao M, 2003. Aspartic peptidase inhibitors: implications in drug development. Crit. Rev. Biochem. Mol. Biol. 38:89-119.
17. Dano WL, 2002. The PyMOL Molecular Graphics System. http://www.pymol.org.
18. Dolle RE, Singh J, Rinker J, Hoyer D, Prasad CVC, Graybill CL, Salvino JM, Helaszek CT, Miller RE, Ator MA, 1994. Aspartyl α-(1-phenyl-3-(trifluoromethyl)-pyrazol-5-yl)-oxy) methyl ketones as interleukin-1β converting enzyme inhibitors. Significance of the P1 and P3 amido nitrogens for enzyme-peptide inhibitor binding. J. Med. Chem. 37(23):3863.
19. Duan JJW, Chen L, Wasserman ZR, Lu Z, Liu R-Q, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR, Decicco CP, 2002. Discovery of β-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor a converting enzyme: design, synthesis, and structure-activity relationships. J. Med. Chem. 45(23):4954.
20. Dunn BM, 2002. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 102:4431-4458.
21. Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B, 2007. Aspartic proteases in drug discovery. Curr. Pharm. Des. 13:271-285.
22. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H, 2003. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. USA 100:5063-5068.
23. Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klingler O, Schlotte V, Weithmann KU, Wendt KU, 2005. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 12(2):181-189.
24. Erlanson DA, Braisted AC, Raphael D, Randal M, Stroud RM, Gordon EM, Wells JA, 2000. Site-directed ligand discovery. Proc. Natl. Acad. Sci. USA 97(17):9367-9372.
25. Finzel BC, Baldwin ET, Bryant Jr GL, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ, Schostarez HJ, Mitchell MA, 1998. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci. 7(10):2118-2126.
26. Fischli W, Clozel JP, el Amrani K, Wostl W, Neidhart W, Stadler H, Branca Q, 1991. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension 18:22-31.
27. Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW, 1991. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc. Natl. Acad. Sci. USA 88:1556-1559.
28. Goschke R, Stutz S, Heinzelmann W, Maibaum J, 2003. The nonchiral bislactim diethoxy ether as highly stereo-inducing synthon for sterically hindered γ-branched α-amino acids: a practical, large-scale route to an intermediate of the novel renin inhibitor aliskiren. Helv. Chim. Acta. 86:2848-2870.
29. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W, 1995. Structure determination and analysis of human neutrophil collagenase complexed with a hydro-xamate inhibitor. Biochemistry 34:14012-14020.
30. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström J-E, Eriksson U, Bredberg U, Teger-Nilsson A-C, 2004. A new oral anticoagulant: the 50 year challenge. Nat. Rev. Drug Discov. 3:649-659.
31. Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera Jr GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW, 1997. Discovery of potent nonpeptidic inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119(25):5818-5827.
32. Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M, Davidsen SK, Fesik SW, 2002. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 45(26):5628-5639.
33. Hardy J, Selkoe DJ, 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
34. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA, 2004. Discovery of an allosteric site in the caspases. Proc. Natl. Acad. Sci. USA 101(34):12461-12466.
35. Heins J, Welker P, Schönlein C, Born I, Hartrodt B, Neubert K, Tsuru D, Barth A, 1988. Mechanism of proline-specific proteinases: (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and protein-specific endopeptidase from flavobacterium meningosep-ticum. Biochem. Biophys. Acta 954:161-169.
36. Holsworth DD, Powell NA, Downing DM, Cai C, Cody WL, Ryan JM, Ostroski R, Jalaie M, Bryant JW, Edmunds JJ, 2005. Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorg. Med. Chem. 13:2657-2664.
37. Hu Y, Xiang JS, Di Grandi MJ, Du X, Ipek M, Laakso LM, Li J, Li W, Rush TS, Schmid J, Skotnicki JS, Tam S, Thomason JR, Wang Q, Levin JI, 2005. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 13(24):6629-6644.
38. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH, 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
39. Kandula VR, Khanlou H, Farthing C, 2005. Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev. Anti Infect. Ther. 3:9-21.
40. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Sinha Roy R, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE, 2005. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48:141-151.
41. Kleinert HD, Rosenberg SH, Baker WR, Stein HH, Klinghofer V, Barlow J, Spina K, Polakowski J, Kovar P, Cohen J, 1992. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 257:1940-1943.
42. Lewis CA, Wolfenden R, 1977. Thiohemiacetal formation by inhibitory aldehydes at the active site of papain. Biochemistry 16:4890-4895.
43. Märki HP, Binggeli A, Bittner B, Bohner-Lang V, Breu V, Bur D, Coassolo PH, Clozel JP, D' Arcy A, Doebeli H, Fischli W, Funk CH, Foricher J, Giller T, Gruninger F, Guenzi A, Guller R, Hartung T, Hirth G, Jenny CH, Kansy M, Klinkhammer U, Lave T, Lohri B, Luft FC, Mervaala EM, Muller DN, Muller M, Montavon F, Oefner CH, Qiu C, Reichel A, Sanwald-Ducray P, Scalone M, Schleimer M, Schmid R, Stadler H, Treiber A, Valdenaire O, Vieira E, Waldmeier P, Wiegand-Chou R, Wilhelm M, Wostl W, Zell M, Zell R, 2001. Piperidine renin inhibitors: from leads to drug candidates. Il Farmaco 56:21-27.
44. Marquis RW, Yamashita DS, Ru Y, Lo Castro SM, Oh H-J, Erhard KF, DesJarlais RL, Head MS, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, Tomaszek TA, Levy MA, Veber DF, 1998. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 41:3563-3567.
45. Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh H-J, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K, Proksch J, Ward K, Smith B, Levy M, Cummings MD, Haltiwanger RC, Trescher G, Wang B, Hemling ME, Quinn CJ, Cheng H-Y, Lin F, Smith WW, Janson CA, Zhao B, McQueney MS, D'Alessio K, Lee C-P, Marzulli A, Dodds RA, Blake S, Hwang S-M, James IE, Gress CJ, Bradley BR, Lark MW, Gowen M, Veber DF, 2001. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. 44:1380-1395.
46. Maskos K, 2005. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 87(3-4):249-263.
47. Matter H, Schwab W, Barbier D, Billen G, Haase B, Neises B, Schudok M, Thorwart W, Schreuder H, Brachvogel V, Loenze P, Weithmann KU, 1999. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and x-ray structure analysis. J. Med. Chem. 42(11):1908-1920.
48. Matthews BW, 1988. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 21:333-340.
49. McGrath ME, Klaus JL, Barnes MG, Bromme D, 1997. Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol. 4:105-109.
50. Miller A, Askew M, Beckett RP, Bellamy CL, Bone EA, Coates RE, Davidson AH, Drummond AH, Huxley P, Martin FM, Saroglou L, Thompson AJ, van Dijk SE, Whittaker M, 1997. Inhibition of matrix metalloproteinases: an examination of the S1' pocket. Bioorg. Med. Chem. Lett. 7(2):193-198.
51. 13C NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. 108:1350-1351.
52. Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR, 2004. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 43(27):8718-8724.
53. Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, D'Arcy A, Dorn A, Fischli W, Grüninger F, Güller R, Hirth G, Märki H, Mathews S, Müller M, Ridley RG, Stadler H, Vieira E, Wilhelm M, Winkler F, Wostl W, 1999. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol. 6:127-131.
54. Ondetti MA, Rubin B, Cushman DW, 1977. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196(4288):441.
55. Overall CM, Kleifeld O, 2006. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94(7):941-946.
56. Page JM, Macgillivray RT, Di Cera E, 2005. Determinants of specificity in coagulation proteases. J. Thromb. Haemost. 3(11):2401-2408.
57. Palmer JT, Bryant C, Wang D-X, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian Z-Q, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G, 2005. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem. 48:7520-7534.
58. Patchett AA, Cordes EH, 1985. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 57:1-84.
59. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth HU, 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258.
60. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C, 2003. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4(7):544-558.
61. Puerta DT, Cohen SM, 2003. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg. Chem. 42(11):3423-3430.
62. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG, 2000. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 7:493-504.
63. Reeke GN, Hartsuck JA, Ludwig L, Steitz TA, Lipscomb WN, 1967. The structure of carboxypeptidase A VI. Some results at 2.0-A resolution and the complex with Glycyl-Tyrosine at 2.8-A resolution. Proc. Natl. Acad. Sci. 58(6):2220-2226.
64. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
65. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer K-H, Reinemer P, Perzborn E, 2005. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48:5900-5908.
66. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA, 2002. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J.Mol.Biol. 319:173-181.
67. Rüeger H, Stutz S, Göschke R, Spindler F, Maibaum J, 2000. A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate. Tetrahedron Lett. 41:10085-10089.
68. Schechter I, Berger A, 1967. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27(2):157-162.
69. Schröder J, Henke A, Wenzel H, Brandstetter H, Stammler HG, Stammler A, Pfeiffer WD, Tschesche H, 2001. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J. Med. Chem. 44(20):3231.
70. Schwienhorst A, 2006. Direct thrombin inhibitors-a survey of recent developments. Cell. Mol. Life Sci. 63:2773-2791.
71. Stöcker W, Grams F, Baumann U, Reinemer P, Gomis-Rüth FX, McKay DB, Bode W, 1995. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 4(5):823-840.
72. Turk B, 2006. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5(9):785-799.
73. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE, 2003. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46:2774-2789.
74. Wilson KP, Black JA, Thomson JA, Kim EE, Griffith JP, Navia MA, Murcko MA, Chambers SP, Aldape RA, Raybuck SA, Livingston DJ, 1994. Structure and mechanism of interleukin-1 beta converting enzyme. Nature 370(6487):270-275.
75. Wood JM, Criscione L, de Gasparo M, Buhlmayer P, Rueger H, Stanton JL, Jupp RA, Kay J, 1989. CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. J. Cardiovasc. Pharmacol. 14:221-226.
76. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasett V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP, 2003. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308:698-705.
77. Xu J, Ok HO, Gonzalez EJ, Colwell Jr LF, Habulihaz B, He H, Leiting B, Lyona KA, Marsilio F, Patel RA, Wu JK, Thornberry NA, Weber AE, Parmee ER, 2004. Discovery of potent and selective β-homophenylalanine-based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 14:4759-4762.
78. Yamashita DS, Smith WW, Zhao B, Janson CA, Tomaszek TA, Bossard MJ, Levy MA, Oh H-J, Carr TJ, Thompson SC, Ijames CF, Carr SA, McQueney M, D'Alessio KJ, Amegadzie BY, Hanning CR, Abdel-Meguid S, DesJarlais RL, Gleason JG, Veber DF, 1997. Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. 119:11351-11352.
79. Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh H-J, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng H-Y, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF, 2006. Structure-activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J. Med. Chem. 49:1597-1612.
80. Zhang X, Gonnella NC, Koehn J, Pathak N, Ganu V, Melton R, Parker D, Hu S-I, Nam K-Y, 2000. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1. J. Mol. Biol. 301(2):513-524.